BCL2L11 and non-small cell lung carcinoma: The progression free survival following EGFR tyrosine kinase inhibitor treatment of NSCLC was significantly shorter in patients with Bim polymorphism (6.6 months) than those with wild-type Bim (11.9 months) [31].